Although an association between elevated leucocyte count and mortality in patients with ACS (acute coronary syndromes) has been established, the independence of this association from coronary risk factors and C-reactive protein has been inadequately studied. In the present study, this prospective registry included 4329 patients with ACS treated with PCI (percutaneous coronary intervention): 1059 patients with STEMI [ST-segment elevation MI (myocardial infarction)], 1753 patients with NSTEMI (non-STEMI) and 1517 patients with unstable angina. Blood samples were obtained before angiography for leucocyte count and C-reactive protein measurements. The primary outcome of this analysis was 1-year mortality. At 1 year, 345 patients (8 %) had died: 45 patients in the 1st tertile, 93 patients in the 2nd tertile and 207 patients in the 3rd tertile of leucocyte count [Kaplan-Meier estimates of mortality, 3.2 %, 6.4 % and 14.1 % with an OR (odds ratio) = 2.42, 95 % CI (confidence interval)1.78-3.12; P < 0.001 for tertile 3 compared with tertile 2 and an OR = 1.99, 95 % CI 1.77-2.25; P < 0.001 for tertile 2 compared with tertile 1]. The Cox proportional hazards model adjusting for coronary risk factors, ACS presentation, extent of coronary artery disease, C-reactive protein and other covariates identified leucocyte count with a HR (hazard ratio) = 1.05 (95 % CI 1.02-1.07; P < 0.001 for 1000 cells/mm 3 increase in the leucocyte count), but not C-reactive protein (HR = 1.13, 95 % CI 0.95-1.34; P = 0.15 for a 1 tertile increase in the C-reactive protein concentration) as an independent correlate of 1-year mortality. We conclude that elevated leucocyte count, but not C-reactive protein, predicts 1-year mortality independent of cardiovascular risk factors across the entire spectrum of patients with ACS treated with PCI.
INTRODUCTION
Considerable evidence exists that elevated leucocyte count, a non-specific marker of inflammation, is a risk factor for future cardiovascular events in individuals apparently free of cardiovascular disease [1, 2] and a prognostic marker for patients already with cardiovascular disease [3, 4] . In patients with ACS (acute coronary syndromes), an elevated baseline leucocyte count predicts mortality in those with STEMI [ST-segment elevation MI (myocardial infarction)] [5] [6] [7] , NSTEMI (non-STEMI) [8, 9] and unstable angina [8, 10] ; however, several aspects of the association between elevated leucocytes and cardiovascular disease require further investigation. First, although an association between elevated leucocyte count and mortality has almost uniformly been confirmed by various studies, the independence of association, i.e. whether elevated leucocyte count retains its prognostic power after full adjustment for other cardiovascular risk factors, has been inadequately studied [11] or is controversial [12, 13] . Secondly, a comparative assessment of the prognostic value of elevated leucocytes and CRP (C-reactive protein) has not been performed. Thirdly, it is not known whether leucocytes retain their prognostic potential (capacity) in patients under treatment with statin therapy.
The aim of the present study was 3-fold: (i) to test the association between leucocyte count and 1-year mortality across the entire spectrum of patients with ACS after adjustment for traditional cardiovascular risk factors; (ii) to investigate the relationship between leucocyte count and CRP and compare their prognostic discriminatory power in patients with ACS; and (iii) to assess the influence of statin therapy on the relationship between elevated leucocytes and 1-year mortality in patients with ACS.
MATERIALS AND METHODS

Patients
This prospective registry included 4329 patients with ACS who underwent diagnostic coronary angiography and PCI (percutaneous coronary intervention) in the Deutsches Herzzentrum München between September 1997 and December 2006: 1059 patients with STEMI, 1753 patients with NSTEMI and 1517 patients with unstable angina. Patients with acute inflammatory states, known malignancies and advanced kidney disease were not included in the present study. The diagnosis of STEMI was based on the presence of chest pain lasting 20 min associated with typical changes on surface ECG (ST-segment elevation of 0.1 mV in two limb leads or 0.2 mV in two contiguous precordial leads, pathological Q waves, or complete left bundle branch block of new onset). Unstable angina was diagnosed when characteristic chest pain [with an accelerating pattern or prolonged (> 20 min) or recurrent episodes at rest or with minimal effort] was associated with either ST segment depression of 0.1 mV and/or T-wave inversion in two continuous leads in the ECG and with documentation of significant coronary artery disease in the coronary angiography. Diagnosis of NSTEMI required clinical and electrocardiographic criteria similar to those of unstable angina plus elevated troponin T (troponin T level > 0.03 μg/l) or CK (creatine kinase) or CK-MB (CKmyocardial band). Arterial hypertension was defined in the presence of active treatment with antihypertensive medications or documentation of a SBP [systolic BP (blood pressure)] of 140 mmHg and/or DBP (diastolic BP) of 90 mmHg on at least two separate occasions. Hypercholesterolaemia was defined as a documented total cholesterol concentration of 240 mg/dl. Current smokers were defined as those currently smoking tobacco. Diabetes mellitus was defined if patients were under active treatment with insulin or oral hypoglycaemic agents. For those on diet alone, documentation of an abnormal fasting blood glucose or glucose tolerance test was required. Written informed consent was obtained from all patients. The study was carried out in accordance with the Declaration of Helsinki and has been approved by the institutional ethics committee.
Leucocyte count and CRP measurement
Blood samples were obtained at the time of admission (before angiographic examination) for measurement of leucocyte count, high-sensitivity CRP and other biochemical parameters. For patients with STEMI and NSTEMI, time interval [median (25th-75th percentiles)] from the pain onset to admission was 7.8 (3.0-19.0) h. Total leucocyte count was counted in EDTAanticoagulated whole-blood specimens using the Sysmex XE 2100 automated haematology analyser. Measurement of leucocyte count was performed by flow cytometry using a semiconductor laser to detect forward-and sidescattered light information after red blood cell lysis. The plasma concentrations of high-sensitivity CRP were measured with a fully automated latex-enhanced immunoturbidometric assay on a Cobas Integra machine (Roche Diagnostics). The CRP assay has an analytical sensitivity of 0.085 mg/l and a measuring range up to 160 mg/l. The upper limit of the reference range of CRP in healthy adults is 5 mg/l. Other biochemical parameters were measured using routine tests. Laboratory personnel were unaware of the results of clinical diagnosis or other study details.
Angiographic evaluation and stent implantation
Coronary angiography was performed according to standard criteria. Angiographic data were analysed using the same Quantitative Angiographic Core Laboratory. Coronary artery disease was confirmed by the presence of coronary stenoses 50 % lumen obstruction in at least one of the three main coronary arteries. A culprit lesion was described in the presence of an acute occlusion, intraluminal filling defects (or thrombus), ulcerated plaques with contrast-filled pocket protruding into plaque with or without delayed contrast wash-out, extraluminal contrast, dissection or intraluminal flaps [14] . Offline analysis of digital angiograms was performed in the core laboratory using an automated edge detection system (CMS; Medis Medical Imaging Systems). The initial and postprocedural blood flow in the artery owning the culprit lesion was quantified using the TIMI (Thrombolysis in Myocardial Infarction) grading system (definitions used in TIMI trials; available at http://www.timi.org). Global LVEF [LV (left ventricular) ejection fraction] was determined in LV angiograms by using the area-length method.
Stent implantation and periprocedural care were performed according to standard criteria. Bare metal stents were mostly used. Postinterventional antiplatelet therapy consisted of ticlopidine (500 mg/day) or clopidogrel (300 mg or 600 mg as a loading dose followed by 75 mg/day for at least 4 weeks to 6 months) and aspirin (200 mg/day administered orally and continued indefinitely).
End point and follow-up
The primary outcome of this analysis was 1-year mortality. Occurrence of MI, major bleeding and stroke were also assessed. The follow-up protocol after discharge consisted of a phone interview at 1 month after the procedure, a visit at 6 months and a phone interview at 12 months. Information about death was obtained from hospital records, death certificates, or phone contact with relatives of the patient or attending physician. The diagnosis of MI, major bleeding and stroke was made according to the TIMI criteria (definitions used in TIMI trials; available at http://www.timi.org).
Patients were advised to present to the outpatient clinic or their referring physicians if they developed chest pain or other cardiac symptoms. In case of symptoms, at least one clinical, laboratory and electrocardiographic check-up was performed.
Statistical analysis
Values are presented as medians (25th and 75th percentiles) or counts and proportions (percentages). The distribution of the data was analysed with a one-sample Kolmogorov-Smirnov test. Categorical data were compared with a χ 2 test. Continuous data were compared with Kruskal-Wallis rank sum test. One-year mortality was estimated by applying the Kaplan-Meier method and log-rank test which allowed the calculation of ORs (odds ratios) [95 % CIs (confidence intervals) and respective P values] associated with being in various tertiles of the leucocyte count. Heterogeneity in risk prediction by leucocyte count in various subgroups was assessed by using the Breslow-Day test. ROC (receiver operating characteristic) curves were constructed to assess the accuracy of leucocyte count and CRP to predict 1-year mortality. Differences between the areas under the curve were assessed for statistical significance according to the method by DeLong et al. [16] . The Cox proportional hazards model was used to assess the association between leucocyte count and 1-year mortality while adjusting for potential confounders: age, gender, diabetes, arterial hypertension, smoking, hypercholesterolaemia, prior MI, prior coronary artery bypass surgery, ACS type, cardiogenic shock, serum creatinine, CRP, LVEF, multivessel disease, baseline TIMI flow grade, post-PCI TIMI flow grade and leucocyte count. Analyses were performed using the S-plus statistical package (Insightful Corporation). A P value < 0.05 was considered to indicate statistical significance.
RESULTS
Baseline characteristics
Patients were divided into three groups according to tertiles of leucocyte count: 1st tertile (leucocyte count < 6800 cells/mm 3 , n = 1392 patients), 2nd tertile (leucocyte count 6800-9400 cells/mm 3 , n = 1466 patients) and 3rd tertile (leucocyte count > 9400 cells/mm 3 , n = 1471 patients). Baseline demographic and clinical characteristics are shown in Table 1 . Patients in the 3rd tertile of leucocyte count were younger, had a higher proportion of women and of current smokers and had less-often arterial hypertension, hypercholesterolaemia, prior MI and prior coronary artery bypass surgery than patients in lower tertiles. They presented more often with acute MI and cardiogenic shock, and had higher levels of troponin and CK. Angiographic characteristics are shown in Table 2 . Patients in the 3rd tertile of leucocyte count had a lower LVEF and a lower proportion of patients with multivessel disease than patients in the other two tertiles (see Tables 1 and 2 for the remaining characteristics).
Leucocyte count and clinical outcome
Clinical outcome after 30 days is shown in Table 3 . With the increase in the tertiles of leucocyte count from 1 to 3 there was a significant increase in the death rate, major bleeding and stroke. At 1 year, 345 patients (8 %) had died: 45 patients in the 1st tertile, 93 patients in the 2nd tertile and 207 patients in the 3rd tertile of leucocyte count (KaplanMeier estimates of mortality, 3.2 %, 6.4 % and 14.1 % respectively; OR = 2.42, 95 % CI 1.78-3.12; P < 0.001 for tertile 3 compared with tertile 2 and OR = 1.99, 95 % CI 1.77-2.25; P < 0.001 for tertile 2 compared with tertile 1; Figure 1 ). Leucocyte count was 10 800 (7900-14 900) cells/mm 3 in patients who died compared with 7800 (6200-10 100) cells/mm 3 in those who survived 1-year follow-up (P < 0.001). There were no significant differences in the 1-year occurrence of MI according to leucocyte count tertiles: Kaplan-Meier estimates of 2.5 % in the 1st tertile (n = 34), 3.9 % in the 2nd tertile (n = 57) and 3.3 % in the 3rd tertile (n = 48) of leucocyte count.
Subgroup analyses of the relationship between leucocyte count and 1-year mortality are shown in There was no interaction between leucocyte count and any subgroups analysed regarding 1-year mortality. ROC curves were constructed to assess the accuracy of leucocytes and CRP regarding 1-year mortality. The area under the ROC curve was 0.69 (95 % CI 0.65-0.72; P < 0.001) for leucocyte count and 0.65 (95 % CI 0.62-0.69; P < 0.001) for CRP (P = 0.09; Figure 3) .
Results of multivariable analysis
The Cox proportional hazards model was applied to test the independence of association between leucocyte count and 1-year mortality while adjusting for potential confounders (see the Materials and methods section for variables entered into the model). The model showed that leucocyte count was an independent correlate of 1-year mortality with an increase of 5 % of the adjusted risk for every 1000 cell/mm 3 increase in leucocyte count. CRP was not independently associated with 1-year mortality [HR (hazard ratio) = 1.09, 95 % CI 0.92-1.36; P = 0.20]. Significant correlates of 1-year mortality are shown in Table 4 . We repeated the Cox proportional hazards model with leucocyte count and CRP entered as tertiles. Again leucocyte count was independently associated with 1-year mortality with an HR of 1.33 (95 % CI 1.09-1.63; P = 0.006) for a 1 tertile increase in the leucocyte count; conversely, CRP was not independently associated with the 1-year mortality (HR = 1.13, 95 % CI 0.95-1.34; P = 0.15 for a 1 tertile increase in the CRP level).
Leucocyte count and 1-year mortality in patients with and without statins
Statin therapy was prescribed in 3898 patients (90 %): 1301 patients in the 1st tertile, 1338 in the 2nd tertile and 1259 patients in the 3rd tertile of leucocyte count. At 1 year there were 29 deaths among patients in the 1st tertile (2.2 %), 56 deaths among patients in the 2nd tertile (4.2 %) and 71 deaths (5.6 %) among patients in the 3rd tertile of leucocyte count (OR = 1.91, 95 % CI 1.21-3.02; P = 0.004 for tertile 2 compared with tertile 1 and OR = 2.62, 95 % CI 1.69-4.07; P < 0.001 for tertile 3 compared with tertile 1). In 431 patients statins were not prescribed: 91 patients in the 1st tertile, 128 patients in the 2nd tertile and 212 patients in the 3rd tertile. Since in patients dying early after acute event (mostly due to cardiogenic shock) statins were not prescribed, we analysed the association between leucocyte count and 1-year mortality in patients who survived the first 30 days after an acute event. In patients who survived the first 30 days after an acute event, 1-year mortality was 9.6 % (eight out of 83 patients) among patients in the 1st tertile, 9.9 % (ten out of 101 patients) among patients in the 2nd tertile and 20.8 % (20 out of 96 patients) among patients in the 3rd tertile of leucocyte count (OR = 2.46, 95 % CI 1.02-5.94; P = 0.04 for 3rd compared with 1st tertile). 
DISCUSSION
In the present study, we investigated the association between leucocyte count and 1-year mortality using data from a large prospective registry of patients with ACS treated with PCI. The main findings of this study are as follows. (i) In patients with ACS treated with PCI (mostly coronary stenting) an elevated leucocyte count was associated with an increased risk of 1-year mortality. This association was independent of cardiovascular risk factors including other markers of inflammatory status (CRP). We found that for every 1000 cells/mm 3 increase in the leucocyte count, adjusted 1-year mortality was increased by 5 %. Moreover, elevated leucocyte count was associated with higher rates of 30-day mortality, major bleeding and stroke. (ii) Comparative analysis of leucocyte and CRP in the multivariable model (the Cox proportional hazards model) showed that leucocyte count, but not CRP, was an independent correlate of 1-year mortality. (iii) Leucocyte count predicts 1-year mortality in patients with ACS receiving statin therapy.
Multiple studies have demonstrated an association between elevated leucocyte count and the extent of coronary artery disease [8, 17] or increased short-term or long-term risk of death in patients with various presentations of coronary artery disease [5] [6] [7] [8] [9] [10] . A host of mechanisms through which elevated leucocyte count may impact coronary artery disease progression and mortality has been proposed and reviewed by Madjid et al. [11] . In the GRACE (Global Registry of Acute Coronary Events), association between elevated leucocyte count and hospital death or development of congestive heart failure was consistent across the entire spectrum of ACS [18] . Although an association between elevated leucocyte count and mortality is undisputed, the independence of association from other potential confounders remains controversial [12, 13] . In a study by Lloyd-Jones et al. [12] , an association between elevated leucocyte and 1-year mortality in patients with unstable angina was markedly diminished after adjustment for other covariates. Similarly, a study of patients with existing coronary artery disease showed that adjustment for coronary risk factors totally eliminated association between leucocyte count and cardiac mortality [13] . Other studies assumed that the impact of leucocyte on mortality may be mediated by smoking [19] or diabetes [20] . Of note, in the majority of reported studies no adjustment for CRP has been performed. Thus, as previously emphasized by Madjid et al. [11] , there is a need to determine the degree to which leucocyte count is independent to other risk factors.
In the present study of patients with ACS, we performed an adjustment for traditional coronary risk factors, clinical presentation of ACS, extent of coronary artery disease, baseline and post-procedural TIMI flow grade and CRP. We found that, in patients with ACS treated with PCI, elevated leucocyte count predicted 1-year mortality independently of all abovementioned coronary risk factors and clinical covariates. Furthermore, the association between leucocyte count and 1-year mortality was consistent in patients with unstable angina, NSTEMI or STEMI. In this regard our results dovetail with those of the GRACE study [18] in reporting a consistent ability of leucocyte count to predict mortality across the entire spectrum of ACS. Of interest is the finding that elevated leucocyte count was associated with a higher incidence of major bleeding and stroke within the first 30 days following PCI, which may imply that elevated leucocyte count may be involved in the genesis of these serious adverse events in patients with ACS undergoing coronary intervention. In the present study, an association between elevated leucocyte count and occurrence of MI could not be demonstrated. With regard to the lack of association between leucocyte count and future occurrence of MI, the present study is in agreement with a previous study by Mueller et al. [9] in patients with non-ST-segment elevation ACS. In fact, inability of leucocyte count to predict cardiac mortality has been reported [13] , and the present finding may be, at least, one of the putative explanations. Of particular interest was the finding that, after adjustment in the multivariable model, leucocyte count, but not CRP, was an independent correlate of 1-year mortality. Recent studies have also shown that leucocyte count outperformed the CRP in predicting the severity of coronary artery disease [20] and a list of other inflammatory markers such as serum amyloid A, fibrinogen and IL-6 (interleukin-6) in predicting 5-year mortality in patients with ACS [21] . These results clearly demonstrate that leucocyte count, a universally available test, is one of the best markers to assess the inflammatory status and its impact on mortality across the entire spectrum of patients with coronary artery disease.
The impact of statin therapy on the association between leucocyte count and mortality is largely unknown. In the LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) study, leucocyte count predicted cardiac mortality in patients randomized to placebo, but not in those who received pravastatin [22] . In the present study 90 % of patients with ACS received statins within the first year following PCI. A separate analysis in these patients demonstrated that leucocyte count predicted 1-year mortality in patients receiving statins with ORs quite similar to those in the whole group of patients. Reasons for these discrepancies regarding the impact of statin therapy on the power of leucocyte count to predict mortality remain unknown.
The present study does not provide information on the leucocyte count differential. It has previously been reported that the neutrophil-to-lymphocyte ratio may be superior to total leucocyte count in predicting subsequent mortality [23, 24] ; however, other studies have shown that total leucocyte count was a better correlate of long-term outcome (mortality) than individual subtypes of leucocyte count [25] .
In conclusion, the present study has demonstrated that elevated leucocyte count, but not CRP, predicts 1-year mortality independently of risk factors for coronary artery disease across the entire spectrum of ACS. Statin therapy did not abolish the association between leucocyte count and 1-year mortality in these patients.
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